Speaker Profile
MSc, Chief Executive Office, Ibex Medical Analytics
Biography
aJoseph Mossel is CEO and Co-Founder of Ibex Medical Analytics. Together with Co-Founder and CTO Chaim Linhart, he embarked on a journey to transform cancer diagnostics by empowering pathologists with AI insights that help them improve diagnostic accuracy, efficiency and turnaround times. His career in the tech industry spans more than 20 years, starting off in software development and product management followed with leadership positions in startups and large multinational corporations where he has led products from inception all the way to maturity as multi-million-dollar businesses. Joseph has also held a tenure in the non-profit sector, serving as managing director of Israels National Ecosystem Assessment Program.Joseph holds an MSc in computer science from Tel Aviv University, and an MSc in environmental science from VU Amsterdam. He is an alumnus of the Adi Lautman Interdisciplinary Program for Outstanding Students at Tel Aviv University.
Talk
AI in Cancer Diagnostics: Real World Learnings
Ibex Medical Analytics is transforming cancer diagnostics with clinical grade AI-powered solutions for pathology. Deployed globally in routine clinical use, this session will cover key learnings from Ibexs vast customer usage, strategic industry partnerships and collaboration with pharmaceutical and biotechnology companies to enable precision medicine.
AI and Data Sciences Showcase:
Ibex Medical Analytics
Ibex Medical Analytics is transforming cancer diagnostics with clinical grade AI powered solutions for pathology. Empowering clinicians and pathologists, Ibex strives to provide accurate, timely and personalized cancer diagnosis for every patient. Ibex is the first and most widely deployed AI-powered platform in pathology.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
